Diane Potvin

1.8k total citations
41 papers, 1.2k citations indexed

About

Diane Potvin is a scholar working on Oncology, Statistics and Probability and Management Science and Operations Research. According to data from OpenAlex, Diane Potvin has authored 41 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Statistics and Probability and 8 papers in Management Science and Operations Research. Recurrent topics in Diane Potvin's work include Statistical Methods in Clinical Trials (11 papers), Optimal Experimental Design Methods (8 papers) and HIV-related health complications and treatments (7 papers). Diane Potvin is often cited by papers focused on Statistical Methods in Clinical Trials (11 papers), Optimal Experimental Design Methods (8 papers) and HIV-related health complications and treatments (7 papers). Diane Potvin collaborates with scholars based in United States, Canada and United Kingdom. Diane Potvin's co-authors include Julian Falutz, Steven Grinspoon, Pierre Allard, Soraya Allas, Daniel Berger, Michael Somero, Ralph R. Turner, Richard C. Chao, Jean‐Claude Mamputu and Walter W. Hauck and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Diane Potvin

38 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diane Potvin United States 20 274 241 186 183 182 41 1.2k
Karl Brendel France 11 94 0.3× 42 0.2× 90 0.5× 34 0.2× 171 0.9× 19 1.1k
Eric Snoeck Belgium 18 176 0.6× 21 0.1× 93 0.5× 100 0.5× 114 0.6× 44 1.1k
Philippe Jacqmin Belgium 20 253 0.9× 25 0.1× 92 0.5× 26 0.1× 242 1.3× 57 1.5k
Christian Laveille France 14 120 0.4× 24 0.1× 117 0.6× 61 0.3× 117 0.6× 33 1.0k
Janet R. Wade United States 19 116 0.4× 16 0.1× 67 0.4× 34 0.2× 191 1.0× 37 1.0k
Jakob Ribbing Sweden 10 126 0.5× 15 0.1× 96 0.5× 62 0.3× 163 0.9× 21 1.0k
Michael Mosteller United States 18 164 0.6× 45 0.2× 79 0.4× 89 0.5× 64 0.4× 34 1.9k
MO Karlsson Sweden 17 203 0.7× 14 0.1× 81 0.4× 99 0.5× 240 1.3× 29 1.2k
Robert Gagnon United States 23 758 2.8× 39 0.2× 144 0.8× 32 0.2× 896 4.9× 49 2.6k
Tisha Joy Canada 21 532 1.9× 138 0.6× 635 3.4× 437 2.4× 96 0.5× 39 1.7k

Countries citing papers authored by Diane Potvin

Since Specialization
Citations

This map shows the geographic impact of Diane Potvin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diane Potvin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diane Potvin more than expected).

Fields of papers citing papers by Diane Potvin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diane Potvin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diane Potvin. The network helps show where Diane Potvin may publish in the future.

Co-authorship network of co-authors of Diane Potvin

This figure shows the co-authorship network connecting the top 25 collaborators of Diane Potvin. A scholar is included among the top collaborators of Diane Potvin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diane Potvin. Diane Potvin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Konstan, Michael W., Deepika Polineni, James F. Chmiel, et al.. (2024). Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis. Journal of Cystic Fibrosis. 24(1). 83–90.
2.
Potvin, Diane, et al.. (2024). Adaptive designs in dermatology clinical trials: Current status and future perspectives. Journal of the European Academy of Dermatology and Venereology. 38(9). 1694–1703.
3.
Kollmannsberger, Christian, Herbert I. Hurwitz, Lyudmila Bazhenova, et al.. (2022). Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. Targeted Oncology. 18(1). 105–118. 15 indexed citations
4.
Vrana, Caroline, et al.. (2021). Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome. PLoS ONE. 16(3). e0248739–e0248739. 24 indexed citations
5.
Allas, Soraya, Assumpta Caixàs, Christine Poitou, et al.. (2018). AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial. PLoS ONE. 13(1). e0190849–e0190849. 69 indexed citations
6.
Grivas, Petros, Amir Mortazavi, Joel Picus, et al.. (2018). Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 125(4). 533–540. 36 indexed citations
7.
Nemunaitis, John, Hossein Borghaei, Wallace Akerley, et al.. (2017). P2.06-014 Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy. Journal of Thoracic Oncology. 12(1). S1078–S1078. 3 indexed citations
8.
Chan, Emily, E. Gabriela Chiorean, Peter J. O’Dwyer, et al.. (2017). Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemotherapy and Pharmacology. 81(2). 355–364. 36 indexed citations
9.
10.
Potvin, Diane, et al.. (2011). Additional results for ‘Sequential design approaches for bioequivalence studies with crossover designs’. Pharmaceutical Statistics. 11(1). 8–13. 32 indexed citations
11.
Falutz, Julian, Diane Potvin, Jean‐Claude Mamputu, et al.. (2010). Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension. JAIDS Journal of Acquired Immune Deficiency Syndromes. 53(3). 311–322. 52 indexed citations
12.
13.
Falutz, Julian, Soraya Allas, K Blot, et al.. (2007). Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. New England Journal of Medicine. 357(23). 2359–2370. 142 indexed citations
14.
Potvin, Diane, et al.. (2007). Sequential design approaches for bioequivalence studies with crossover designs. Pharmaceutical Statistics. 7(4). 245–262. 62 indexed citations
15.
16.
Kimanani, Ebi K., et al.. (2000). Numerical methods for the evaluation of individual bioequivalence criteria. Statistics in Medicine. 19(20). 2775–2795. 6 indexed citations
17.
Ouellet, Danièle, et al.. (1999). Comparison of Different Methods to Evaluate Population Dose–Response and Relative Potency: Importance of Interoccasion Variability. Journal of Pharmacokinetics and Biopharmaceutics. 27(1). 67–83. 9 indexed citations
18.
Gaudreault, Jacques, et al.. (1998). Truncated Area Under the Curve as a Measure of Relative Extent of Bioavailability: Evaluation Using Experimental Data and Monte Carlo Simulations. Pharmaceutical Research. 15(10). 1621–1629. 19 indexed citations
19.
Dassa, Clément, et al.. (1997). Effects of a Neutral Answer Choice on the Reliability and Validity of Attitude and Opinion Items. Canadian Journal of Program Evaluation. 12(2). 61–80. 10 indexed citations
20.
Kimanani, Ebi K. & Diane Potvin. (1997). A Parametric Confidence Interval for a Moment-Based Scaled Criterion for Individual Bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics. 25(5). 595–614. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karl Brendel Breakdown of academic impact, for papers by Eric Snoeck Breakdown of academic impact, for papers by Philippe Jacqmin Breakdown of academic impact, for papers by Christian Laveille Breakdown of academic impact, for papers by Janet R. Wade Breakdown of academic impact, for papers by Jakob Ribbing Breakdown of academic impact, for papers by Michael Mosteller Breakdown of academic impact, for papers by MO Karlsson Breakdown of academic impact, for papers by Robert Gagnon Breakdown of academic impact, for papers by Tisha Joy
Rankless by CCL
2026